<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2547">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444700</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 33109220.7.0000.0068</org_study_id>
    <nct_id>NCT04444700</nct_id>
  </id_info>
  <brief_title>A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic</brief_title>
  <acronym>RAPID-BRAZIL</acronym>
  <official_title>Utilização da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com síndrome respiratória Aguda Grave Por COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Published papers evaluating coagulopathy on COVID-19 patients indicate a higher incidence of
      thromboembolic events, sometimes, as high as 20%. Such events increase ICU admissions and are
      associated with death.

      Considering the importance of thromboembolic events concurring to deteriorate clinical state,
      we propose to conduct a parallel pragmatic open-label randomized controlled trial to
      determine the effect of therapeutic anticoagulation compared to standard care in hospitalized
      patients with COVID-19 and with low oxygen saturation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite main outcome</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome of ICU admission or all-cause death</measure>
    <time_frame>28 days</time_frame>
    <description>Composite outcome of ICU admission or all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who received red blood cell transfusion</measure>
    <time_frame>28 days</time_frame>
    <description>Red Blood Cell transfusion (greater than or equal to 1 unit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.</measure>
    <time_frame>28 days</time_frame>
    <description>Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital-free days alive up to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Hospital-free days alive up to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU-free days alive up to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>ICU-free days alive up to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days alive up to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days alive up to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with venous thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Venous thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with arterial thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Arterial thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with heparin induced thrombocytopenia</measure>
    <time_frame>28 days</time_frame>
    <description>Heparin induced thrombocytopenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>COVID</condition>
  <condition>Coronavirus Infection</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>Thromboembolism, Venous</condition>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>Therapeutic anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic anticoagulation with enoxaparin 1 mg/Kg BID will be administered until discharged from the hospital or after 7 days, whichever is longer, or death.
If the patient is admitted to the ICU or requiring ventilatory support, we recommend the continuation of the allocated treatment as long as the treating physician is in agreement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care will be administered until discharged from the hospital or after 7 days, whichever is longer, or death.
If BMI less than 40 Kg/m², the treating physician may select one of the following options considered appropriate and available in Brazil:
Enoxaparin 40 mg once daily, enoxaparin 60 mg once daily, UFH 5,000 twice daily, UFH 5,000 thrice daily.
If BMI equals to or greater than 40 Kg/m², the treating physician may select one of the following options considered appropriate and available in Brazil:
Enoxaparin 40 mg BID, UFH 7,500 TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic anticoagulation</intervention_name>
    <description>Therapeutic anticoagulation with enoxaparin 1 mg/Kg twice daily.</description>
    <arm_group_label>Therapeutic anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory confirmed diagnosis of SARS-CoV-2 as per the World Health Organization
             protocols;

          -  Admitted to hospital;

          -  ≥18 years of age;

          -  Oxygen saturation lower than 94%;

          -  Informed consent from the patient (or legally authorized substitute decision maker).

        Exclusion Criteria:

          -  pregnancy;

          -  hemoglobin &lt;80 g/L in the last 72 hours;

          -  platelet count &lt;50 x 109/L in the last 72 hours;

          -  known fibrinogen &lt;1.5 g/L (if testing deemed clinically indicated by the treating
             physician prior to the initiation of anticoagulation);

          -  known INR &gt;1.8 (if testing deemed clinically indicated by the treating physician prior
             to the initiation of anticoagulation);

          -  patient already on intermediate dosing of LMWH that cannot be changed (determination
             of what constitutes an intermediate dose is to be at the discretion of the treating
             clinician taking the local institutional thromboprophylaxis protocol for high risk
             patients into consideration);

          -  patient already on therapeutic anticoagulation at the time of screening (low or high
             dose nomogram UFH, LMWH, warfarin, direct oral anticoagulant (any dose of dabigatran,
             apixaban, rivaroxaban, edoxaban);

          -  patient on dual antiplatelet therapy, when one of the agents cannot be stopped safely;

          -  known bleeding within the last 30 days requiring emergency room presentation or
             hospitalization;

          -  known history of a bleeding disorder of an inherited or active acquired bleeding
             disorder;

          -  known history of heparin-induced thrombocytopenia;

          -  known allergy to UFH or LMWH;

          -  admitted to the intensive care unit at the time of screening;

          -  treated with non-invasive positive pressure ventilation or invasive mechanical
             ventilation at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Juni, MD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elnara M Negri, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratório de Investigação Médica da FMUSP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heraldo P de Souza, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Disciplina de Emergências Clínicas, Hospital das Clínicas da FMUSP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hassan Rahhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Disciplina de Emergências Clínicas, Hospital das Clínicas da FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassan Rahhal, MD</last_name>
    <phone>+551126619033</phone>
    <email>hassan.r@hc.fm.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05402-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Rahhal, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

